Patents by Inventor Robin Callan
Robin Callan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9216247Abstract: Acid concentrates, and dialysate compositions prepared therefrom, contain citric acid and an effective amount of a buffering agent selected from acetate and/or lactate. The buffering agent allows a physiologically acceptable amount of citrate to maintain the desired pH of the dialysate.Type: GrantFiled: October 10, 2013Date of Patent: December 22, 2015Assignee: Advanced Renal TechnologiesInventors: Robin Callan, Walter A. Van Schalkwijk, James J. Cole
-
Publication number: 20150246167Abstract: Acid concentrates, and dialysate compositions prepared therefrom, contain citric acid and an effective amount of a buffering agent selected from acetate and/or lactate. The buffering agent allows a physiologically acceptable amount of citrate to maintain the desired pH of the dialysate.Type: ApplicationFiled: January 8, 2010Publication date: September 3, 2015Applicant: Advanced Renal TechnologiesInventors: Robin Callan, Walter A. Van Schalkwijk, James J. Cole, Suhail Ahmad
-
Publication number: 20150246168Abstract: Acid concentrates, and dialysate compositions prepared therefrom, contain citric acid and an effective amount of a buffering agent selected from acetate and/or lactate. The buffering agent allows a physiologically acceptable amount of citrate to maintain the desired pH of the dialysate.Type: ApplicationFiled: January 8, 2010Publication date: September 3, 2015Applicant: Advanced Renal TechnologiesInventors: Robin Callan, Walter A. Van Schalkwijk, James J. Cole
-
Publication number: 20150083664Abstract: The dose of dialysis in terms of urea clearance is marginal in many hemodialysis patients, and metabolic acidosis as determined by the pre-dialysis serum HCO3 level is common. A dialysate that included citric acid rather than acetic acid as acidifying agent provides superior performance properties. Citrate-containing dialysate was used exclusively in 22 hemodialysis patients. Initially, only 8 of the 22 patients had a pre-dialysis serum HCO3>23 mEq/L (lower limit of normal), however, after 12 weeks of dialysis using the citrate-containing dialysate, the serum HCO3 normalized in 15 patients (p=0.0001, Chi-square). Dialysis variables were kept constant in 19 of the patients, who also used and reused the same dialyzer model throughout. In these patients, the initial average urea reduction ratio (URR) was 68.5±5.9%, and after treatment with the citrate dialysate disclosed herein, this ratio had increased to 73±5.3% (p<0.03). SpKt/V, calculated using the Daugirdas II formula, also increased from 1.23±0.Type: ApplicationFiled: October 6, 2014Publication date: March 26, 2015Inventors: Robin Callan, James J. Cole
-
Publication number: 20140328948Abstract: Acid concentrates, and dialysate compositions prepared therefrom, contain citric acid and an effective amount of a buffering agent selected from acetate and/or lactate. The buffering agent allows a physiologically acceptable amount of citrate to maintain the desired pH of the dialysate.Type: ApplicationFiled: December 6, 2013Publication date: November 6, 2014Applicant: Advanced Renal TechnologiesInventors: Robin Callan, Walter A. Van Schalkwijk, James J. Cole
-
Patent number: 8864699Abstract: The dose of dialysis in terms of urea clearance is marginal in many hemodialysis patients, and metabolic acidosis as determined by the pre-dialysis serum HCO3 level is common. A dialysate that included citric acid rather than acetic acid as acidifying agent provides superior performance properties. Citrate-containing dialysate was used exclusively in 22 hemodialysis patients. Initially, only 8 of the 22 patients had a pre-dialysis serum HCO3>23 mEq/L (lower limit of normal), however, after 12 weeks of dialysis using the citrate-containing dialysate, the serum HCO3 normalized in 15 patients (p=0.0001, Chi-square). Dialysis variables were kept constant in 19 of the patients, who also used and reused the same dialyzer model throughout. In these patients, the initial average urea reduction ratio (URR) was 68.5±5.9%, and after treatment with the citrate dialysate disclosed herein, this ratio had increased to 73±5.3% (p<0.03). SpKt/V, calculated using the Daugirdas II formula, also increased from 1.23±0.Type: GrantFiled: December 20, 2010Date of Patent: October 21, 2014Assignee: Advanced Renal TechnologiesInventors: Robin Callan, James J. Cole
-
Publication number: 20140034873Abstract: Acid concentrates, and dialysate compositions prepared therefrom, contain citric acid and an effective amount of a buffering agent selected from acetate and/or lactate. The buffering agent allows a physiologically acceptable amount of citrate to maintain the desired pH of the dialysate.Type: ApplicationFiled: October 10, 2013Publication date: February 6, 2014Applicant: Advanced Renal TechnologiesInventors: Robin Callan, Walter A. Van Schalkwijk, James J. Cole
-
Publication number: 20120006748Abstract: Dry acid-concentrate compositions comprising citrate and their use in preparing dialysate compositions and in performing hemodialysis is disclosed.Type: ApplicationFiled: December 21, 2010Publication date: January 12, 2012Applicant: ADVANCED RENAL TECHNOLOGIESInventors: Robin Callan, Walter A. Van Schalkwijk, James J. Cole, Suhail Ahmad
-
Publication number: 20110172583Abstract: The dose of dialysis in terms of urea clearance is marginal in many hemodialysis patients, and metabolic acidosis as determined by the pre-dialysis serum HCO3 level is common. A dialysate that included citric acid rather than acetic acid as acidifying agent provides superior performance properties. Citrate-containing dialysate was used exclusively in 22 hemodialysis patients. Initially, only 8 of the 22 patients had a pre-dialysis serum HCO3>23 mEq/L (lower limit of normal), however, after 12 weeks of dialysis using the citrate-containing dialysate, the serum HCO3 normalized in 15 patients (p=0.0001, Chi-square). Dialysis variables were kept constant in 19 of the patients, who also used and reused the same dialyzer model throughout. In these patients, the initial average urea reduction ratio (URR) was 68.5±5.9%, and after treatment with the citrate dialysate disclosed herein, this ratio had increased to 73±5.3% (p<0.03). SpKt/V, calculated using the Daugirdas II formula, also increased from 1.23±0.Type: ApplicationFiled: December 20, 2010Publication date: July 14, 2011Applicant: Advanced Renal TechnologiesInventors: Robin CALLAN, James J. Cole
-
Patent number: 7862530Abstract: The dose of dialysis in terms of urea clearance is marginal in many hemodialysis patients, and metabolic acidosis as determined by the pre-dialysis serum HCO3 level is common. A dialysate that included citric acid rather than acetic acid as acidifying agent provides superior performance properties. Citrate-containing dialysate was used exclusively in 22 hemodialysis patients. Initially, only 8 of the 22 patients had a pre-dialysis serum HCO3>23 mEq/L (lower limit of normal), however, after 12 weeks of dialysis using the citrate-containing dialysate, the serum HCO3 normalized in 15 patients (p=0.0001, Chi-square). Dialysis variables were kept constant in 19 of the patients, who also used and reused the same dialyzer model throughout. In these patients, the initial average urea reduction ratio (URR) was 68.5±5.9%, and after treatment with the citrate dialysate disclosed herein, this ratio had increased to 73±5.3% (p<0.03). SpKt/V, calculated using the Daugirdas II formula, also increased from 1.23±0.Type: GrantFiled: November 8, 2004Date of Patent: January 4, 2011Assignee: Advanced Renal TechnologiesInventors: Robin Callan, James J. Cole
-
Publication number: 20100176340Abstract: Acid concentrates, and dialysate compositions prepared therefrom, contain citric acid and an effective amount of a buffering agent selected from acetate and/or lactate. The buffering agent allows a physiologically acceptable amount of citrate to maintain the desired pH of the dialysate.Type: ApplicationFiled: January 8, 2010Publication date: July 15, 2010Applicant: ADVANCED RENAL TECHNOLOGIESInventors: Robin Callan, Walter A. Van Schalkwijk, James J. Cole, Suhail Ahmad
-
Publication number: 20100170849Abstract: Acid concentrates, and dialysate compositions prepared therefrom, contain citric acid and an effective amount of a buffering agent selected from acetate and/or lactate. The buffering agent allows a physiologically acceptable amount of citrate to maintain the desired pH of the dialysate.Type: ApplicationFiled: January 8, 2010Publication date: July 8, 2010Applicant: ADVANCED RENAL TECHNOLOGIESInventors: Robin Callan, Walter A. Van Schalkwijk, James J. Cole, Suhail Ahmad
-
Patent number: 7670491Abstract: Acid concentrates, and dialysate compositions prepared therefrom, contain citric acid and an effective amount of a buffering agent selected from acetate and/or lactate. The buffering agent allows a physiologically acceptable amount of citrate to maintain the desired pH of the dialysate.Type: GrantFiled: June 24, 2003Date of Patent: March 2, 2010Assignee: Advanced Renal TechnologiesInventors: Robin Callan, Walter A. van Schalkwijk, James J. Cole, Suhail Ahmad
-
Publication number: 20050119598Abstract: The dose of dialysis in terms of urea clearance is marginal in many hemodialysis patients, and metabolic acidosis as determined by the pre-dialysis serum HCO3 level is common. A dialysate that included citric acid rather than acetic acid as acidifying agent provides superior performance properties. Citrate-containing dialysate was used exclusively in 22 hemodialysis patients. Initially, only 8 of the 22 patients had a pre-dialysis serum HCO3>23 mEq/L (lower limit of normal), however, after 12 weeks of dialysis using the citrate-containing dialysate, the serum HCO3 normalized in 15 patients (p=0.0001, Chi-square). Dialysis variables were kept constant in 19 of the patients, who also used and reused the same dialyzer model throughout. In these patients, the initial average urea reduction ratio (URR) was 68.5±5.9%, and after treatment with the citrate dialysate disclosed herein, this ratio had increased to 73±5.3% (p<0.03). SpKt/V, calculated using the Daugirdas II formula, also increased from 1.23±0.Type: ApplicationFiled: November 8, 2004Publication date: June 2, 2005Applicant: Advanced Renal TechnologiesInventors: Robin Callan, James Cole
-
Publication number: 20040060865Abstract: Acid concentrates, and dialysate compositions prepared therefrom, contain citric acid and an effective amount of a buffering agent selected from acetate and/or lactate. The buffering agent allows a physiologically acceptable amount of citrate to maintain the desired pH of the dialysate.Type: ApplicationFiled: June 24, 2003Publication date: April 1, 2004Inventors: Robin Callan, Walter A. van Schalkwijk, James J. Cole, Suhail Ahmad
-
Patent number: 6610206Abstract: Acid concentrates, and dialysate compositions prepared therefrom, contain citric acid and an effective amount of a buffering agent selected from acetate and/or lactate. The buffering agent allows a physiologically acceptable amount of citrate to maintain the desired pH of the dialysate.Type: GrantFiled: October 19, 1999Date of Patent: August 26, 2003Assignee: Advanced Renal TechnologiesInventors: Robin Callan, Walter A. van Schalkwijk, James J. Cole